MARCKS and lung disorder: Since pharmacological regulation of MARCKS is achievable through selective peptides,14, 16 which are currently in human clinical trials for lung disease, it is likely that modulation of MARCKS using these peptides in in vivo studies may be feasible and that these studies might not only offer important insights into potential cardiovascular side effects of these peptides when treating lung diseases and but also the potential effectiveness of these peptides in regulating cardiovascular parameters and vascular disease.